Despite the fact that a growing number of developers and CROs have now had three to five years of experience with these strategic relationships, speed and efficiency improvements and cost savings remain the exception.
"Despite the fact that a growing number of developers and CROs have now had three to five years of experience with these strategic relationships, speed and efficiency improvements and cost savings remain the exception," said Ken Getz, associate professor and director of sponsored research at Tufts CSDD in response to its most recent management report. And while strategic relationships between drug developers and contract research organizations(CROs) are generating innovative approaches to clinical trial design and execution, Getz added, "Old habits are slow to change and most drug developers are supporting practices that prevent them from integrating their strategic relationships and leveraging the value of these important collaborative models."
The study also found:
Read the full release here.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.